Replies to post #1547 on Momenta Pharmaceuticals, Inc. (MNTA)

[HattieTheWitch]

This has been discussed ad nauseam. The FTC would object vociferously to having one company own both branded Copaxone and the obligate technology for making a generic version of Copaxone for the US market.

Yes, that's why I stated "While the FTC would no doubt disallow TEVA from "cornering the market" on generic versions of enox (and Copaxone?)..."

So, although those hurdles would have to be overcome, there would be many more things about a buyout which would be beneficial to TEVA, IMHO.

Other than the trouble of handling the Copaxone (and m-enox) matters, there is substantial benefit to TEVA should they make such an acquisition.

Do you disagree?

Are there more things standing in TEVA's way than m-enox and generic Copaxone?

[poorgradstudent]

This has been discussed ad nauseam. The FTC would object vociferously to having one company own both branded Copaxone and the obligate technology for making a generic version of Copaxone for the US market.

I agree with that.

But let's pretend I'm Teva. Speaking hypothetically, if my biggest concern re: MNTA is m-copaxone, then I would buy the company now and divest the m-copaxone "franchise." That may let me stay on good terms with the regulators, and by divesting m-copaxone but keeping the people, i basically make it hard for the purchaser of the m-copaxone estate to capitalize on their asset.